1Gaspoz JM. Costs and benefits of heart failure treatment. SchweizMed Wochenschr, 1999,129(4):131.
2Connor CM, Gattis WA, Swedberg K. Current and novel Pharma-cologic approaches in advanced heart failure. Am Heart J, 1998 ,135(6 Pt 2 Su):S249.
3Coodley E. Newer drug therapy for congestive heart failure. ArchIntern Med 1999 , 159(11): 1177.
4Unterberg C, Kreuzer H, Buchwald AB. The renin-angiotensin sys-tem in cardiovascular diseases. Med Klin, 1998, 93(7):416.
5Garg R, Yusuf S. Overview of randomized trials of angiotensin-con-vetting enzyme inhibitors on mortality and morbidity in patients withheart failure. Collaborative Group on ACE Inhibitor Trials. JAMA,1995, 273(18): 1450.
6Brunner La, Rocca HP, Vaddadi G, et al. Recent insight into ther-apy of congestive heart failure: focus on ACE inhibition and an-giotensin-Ⅱ antagonism. J Am Coll Cardiol, 1999,33(5): 1163.
7Brown NJ, Vaughan DE. Angiotensin-converting enzyme in-hibitors. Circulation, 1998, 97(14):1411.
8Toole L, Stewart M, Padfield P, et al. Effect of the insertion/dele-tion polymorphism of the angiotensin-converting enzyme gene on re-sponse to angiotensin-converting. J Cardiovasc Pharmacol, 1998, 32(6):988.
9Van Veldhuisen DJ, Genth Zotz S, Brouwer J, et al. High-versuslow-dose ACE inhibition in chronic heart failure: a double-blind,placebo-controlled study of imidapril. J Am Coll Cardiol, 1998, 32(7): 1811.
10Davie AP, AU-Dargie HJ, McMurray JJ. Role of bradykinin in thevasodilator effects of losartan and enalapril in patients with heartfailure. Circulation, 1999, 100(3):268.
3Schmitz D, Berk B C. Angiotensin Ⅱ signal transduction stimulation of multiple mitogen activated protein kinase pathways[J]. Trendsendocrinol Metab, 1997,8 ( 2 ) :261 - 266.
4Joel M, Neutel M D, Martin P,et al. Efficacy of valsartan in patients aged≥65 years with systolic hypertension[J]. Clin Ther, 2000 ,22(8) :961-969.
5Allen D , Charles B, David P. A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin Ⅱ rceptor blocker [ J ]. Clin Ther, 2002, 24 ( 6 ) :930 - 942.
6Nobuo T , Nobuhisa A , Katsuhito T. A single-center, open-label, randomized, parallel-group study assessing the differences between an angiotensin 1I receptor antagonist and an angiotensin-converting enzyme inhibitorin hypertensive patients with congestive heart failure : the research for efficacy of angiotensin Ⅱ receptor antagonist in hypertensive patients with congestive heart failure study [ J ]. Curr Ther Res, 2003,64(2) : 81 -95.
7Salim Y , Dphil . From the hope to the ontarget and the transcendstudies: challenges in improving prognosis[ J]. Am J Cardiol, 2002, 89 (2) :560-565.
8Pitt B. Randomised trial of losartan versus captopril in patients over 65 with heart failure ( evaluation of losartan in the elderly, eliet) [ J ]. Lancet, 1997,349:747.
9Stephen G, Ball M D, William B ,et al. Debate: angiotensinconverting enzyme inhibitors versus angiotensin Ⅱ receptor blockers-a gap in evidence-based medicine[ J]. Am J Cardiol,2003, 91 (10) :15 -21.
10Coats A J. Angiotensin type-1 receptor blockers in heart failure[J]. Prog Cardiovasc Dis, 2002,44(4) :231 -242.
